Studies have confirmed that mTOR inhibitor (everolimus) combined with trastuzumab reversed trastuzumab resistance via the hyperactivated PI3K-AKT-MTOR pathway due to PTEN deficiency in patients with HER2-positive advanced breast cancer [33]. The gene discussed is AKT1; the disease is breast cancer.